Omari Joud Y, Nevins Marc L, Smith Gideon P, Menon Reshma S, Woo Sook-Bin
Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA.
StrataDx, Lexington, MA, USA.
Head Neck Pathol. 2025 May 31;19(1):71. doi: 10.1007/s12105-025-01803-0.
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytic disease characterized by xanthogranulomatous infiltration of multiple organ systems by histiocytes that are negative for langerin (CD207) and CD1a. V600E mutation is present in 54% of the cases. The disease most commonly affects males in their 5th and 7th decades and bone is involved in 96% of cases although there have been only 8 reported cases of ECD involving the jaws. This is a case of ECD in a 57-year-old male who presented for extractions and implant placement. Radiographic examination revealed extensive bone loss in the posterior mandible and maxilla. Biopsy of the lytic lesions showed infiltration by epithelioid histiocytes with Touton-type multinucleated giant cells that were positive for BRAF and CD163 and negative for CD1a, consistent with the patient’s known history of ECD. He had been diagnosed with ECD 8 years prior with involvement of the long bones and subsequently the skin. The patient started vemurafenib treatment in July 2020 for progressive disease and his disease remains stable. Of the 8 previously reported cases involving the jaws, the median age at diagnosis was 35 years and both genders were equally affected. Reports describe multiple, often bilateral, mixed lytic-sclerotic lesions. Both the mandible and maxilla were affected in 75% of the cases and the mandible alone was involved in one case. None of the cases affected the maxilla alone. Current management includes the use of BRAF inhibitors and MEK inhibitors in the presence of mutations.
厄德里希-切斯特病(ECD)是一种罕见的非朗格汉斯细胞组织细胞增多症,其特征是组织细胞对朗格素(CD207)和CD1a呈阴性,对多个器官系统进行黄色瘤样浸润。54%的病例存在V600E突变。该病最常影响50多岁和70多岁的男性,96%的病例累及骨骼,尽管仅有8例ECD累及颌骨的报道。这是一例57岁男性的ECD病例,该患者因拔牙和种植体植入前来就诊。影像学检查显示下颌骨后部和上颌骨广泛骨质流失。溶骨性病变的活检显示上皮样组织细胞浸润,伴有图顿型多核巨细胞,BRAF和CD163呈阳性,CD1a呈阴性,与患者已知的ECD病史一致。他在8年前被诊断为ECD,当时累及长骨,随后累及皮肤。该患者于2020年7月开始使用维莫非尼治疗进展性疾病,其病情保持稳定。在先前报道的8例累及颌骨的病例中,诊断时的中位年龄为35岁,男女受累情况相同。报告描述为多个,通常为双侧的混合性溶骨-硬化性病变。75%的病例下颌骨和上颌骨均受累,1例仅累及下颌骨。无一例仅累及上颌骨。目前的治疗方法包括在存在突变的情况下使用BRAF抑制剂和MEK抑制剂。